^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NMS-293

    i
    Other names: NMS-293, NMS-03305293, NMS-P293, NMS03305293, NMS293, NMSP293, NMS 03305293, NMS 293, NMS P293
    Associations

    News

    Trials
    Company:
    EMD Serono, Nerviano Medical Sciences
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=52, Terminated, Nerviano Medical Sciences | N=150 --> 52 | Trial completion date: Dec 2024 --> May 2024 | Active, not recruiting --> Terminated; The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    NMS-293
    8ms
    Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, Nerviano Medical Sciences | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024
    Enrollment closed • Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    NMS-293
    9ms
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Nerviano Medical Sciences | N=75 --> 150
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation
    |
    temozolomide • NMS-293
    over1year
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Nerviano Medical Sciences | N=125 --> 75
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation
    |
    temozolomide • NMS-293
    over2years
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=125, Recruiting, Nerviano Medical Sciences | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • lomustine • NMS-293
    almost3years
    Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Nerviano Medical Sciences | N=100 --> 150 | Trial completion date: Apr 2023 --> Dec 2023 | Trial primary completion date: Nov 2021 --> Jul 2023
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    NMS-293
    over3years
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=125, Not yet recruiting, Nerviano Medical Sciences | Initiation date: May 2021 --> Sep 2021
    Clinical • Trial initiation date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    temozolomide • lomustine • NMS-293
    over3years
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=125, Not yet recruiting, Nerviano Medical Sciences
    Clinical • New P1/2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    temozolomide • lomustine • NMS-293
    almost4years
    Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Nerviano Medical Sciences | Trial completion date: Jun 2022 --> Apr 2023 | Trial primary completion date: Apr 2021 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    NMS-293